Hematology/Oncology Department
Research Studies Open for Enrollment
|
UCSF Benioff Children's Hospital Oakland Hematology/Oncology Department Research Studies Open for Enrollment |
Date: 07/13/2020 |
|---|
| Title | ID/Protocol | NCT/Phase | Sponsor | P.I. | Contact |
| NEURO-ONCOLOGY | |||||
|---|---|---|---|---|---|
| Oncology, Neuro-Oncology | |||||
| Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients | ACNS1422 | 02724579 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Neuro-Oncology, Solid Tumors | |||||
| Clinical/Molecular Risk-Tailored Intensive, Compressed Induction Chemotherapy Followed by Consolidation Randomization To Single-Cycle or 3 Tandem Cycles of Marrow-Ablative Chemo with Hematopoietic Progenitor Cell Rescue | Head-Start-4 | NCT02875314 Phase 4 | Next Consortium, Nationwide Children's | Caroline Hastings, MD | Effie Bourgin |
| ONCOLOGY | |||||
| Pediatric Tissue Bank at the Children's Hospital & Research Center Oakland | ONC Tissue Bank | N/A | Jon Rowland, MD | ||
| The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) | ACCL1633 | N/A Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology | |||||
| Key Adverse Events after Childhood Cancer | ALTE03N1 | N/A N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer | ALTE07C1 | 00772200 N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program | DCP-001 | N/A N/A | NCORP | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Leukemia | |||||
| International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones | AALL1631 | N/A Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome | AAML1531 | 02521493 Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Neuro-Oncology | |||||
| A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations | ACNS1721 | 03581292 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Neuro-Oncology, Leukemia, Lymphoma, Solid Tumors | |||||
| A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer | ALTE1631 | 03223753 Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Establishing Continuous Cell Lines and xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies | ABTR04B1 | N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study | APEC14B1 | N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Oncology: Early Phase, Lymphoma, Solid Tumors | |||||
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol | APEC1621SC | N/A Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Oncology: Early Phase, Solid Tumors | |||||
| Master, NCI COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | APEC1621 | N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Solid Tumors | |||||
| Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma | ALTE16C1 | 03206450 N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| LEAHRN (Late Effects After High-Risk Neuroblastoma) Study | ALTE15N2 | N/A N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Neuroblastoma Classification Biology Studies | ANBL00B1 | N/A | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) | AHEP1531 | N/A Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | AGCT1531 | 03067181 Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alt. w. Vincristine/Irinotecan (VI) Vs VAC/VI Plus Temsirolimus (TORI, Torisel) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) | ARST1431 | N/A Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma | ANBL1232 | 02176967 Phase 3 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| ONCOLOGY: EARLY PHASE | |||||
| A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard Immunotherapy with or w/o DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma | NMTRC012 | NCT02559778 Phase 2 | Beat Childhood Cancer (BCC) | Anu Agrawal, MD | Jennifer Michlitsch, MD |
| Leukemia, Lymphoma | |||||
| Pilot Study of Mitoxantrone in combination with Clofarabine in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma | MITCL | NCT01842672 Phase 1/2a | New York Medical College | Jennifer Michlitsch, MD | Jennifer Michlitsch, MD |
| Lymphoma, Solid Tumors | |||||
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of tazemetostat for patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex | APEC1621C | NCT03213665 Phase 2 | Children's Oncology Group | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Neuro-Oncology, Oncology: Early Phase, Lymphoma, Solid Tumors | |||||
| NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) - PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONS | APEC1621K | NCT04195555 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Oncology: Early Phase, Lymphoma, Solid Tumors | |||||
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations | APEC1621J | 03698994 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations | APEC1621B | NCT03210714 Phase 2 | Children's Oncology Group | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions | APEC1621A | NCT03213704 Phase 2 | Children's Oncology Group | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LY3023414 in Solid Tumors | APEC1621D | NCT03155620 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes | APEC1621I | N/A Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes | APEC1621H | NCT03233204 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations | APEC1621G | NCT03220035 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Oncology, Solid Tumors | |||||
| Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | ADVL1622 | NCT02867592 Phase 2 | Children's Oncology Group (COG) | Carla Golden, MD | Diane Olszewski (510-428-3885 x 3246) |
| Solid Tumors | |||||
| Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine | NMTRC-014-DFMO | NCT02679144 Phase 2 | Beat Childhood Cancer (BCC) | Anu Agrawal, MD | Anu Agrawal, MD (510-428-3885 x3539) |
| Pazopanib in Combination with Irinotecan and Temozolomide for Children and Young Adults with Relapsed or Refractory Sarcoma | PAZIT | NCT03139331 Phase 1 | University of California, San Francisco | Jennifer Michlitsch, MD | Jennifer Michlitsch, MD |
| Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma | TB-403 | NCT02748135 Phase 1/2a | Beat Childhood Cancer (BCC) and Oncurious NV | Jennifer Michlitsch, MD | Jennifer Michlitsch, MD (510-428-3885 x3264) |
| STEM CELL TRANSPLANTATION AND CELLULAR THERAPY | |||||
| Oncology | |||||
| Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation | ONC1401 | NCT02646839 Phase 1/2 | Pediatric Blood and Marrow Transplatn Consortium | Nahal Rose Lalefar, MD | Marci Moriarty, RN (510-428-3385 x5396) |
| Oncology: Early Phase, Leukemia | |||||
| Pediatric and Young Adult Leukemia Adoptive Therapy. A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia | PLAT-02 | NCT02028455 Phase 1/2 | Seattle Children's Hospital | Anu Agrawal, MD | Marci Moriarty, RN (510-428-3385 x5396) |